Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future therapies for heart failure.

Robin J Trupp1, William T Abraham, Sumant Lamba

  • 1The Heart and Lung Research Institute, The Ohio State University 473 West 12th Avenue, Columbus, OH 43210, USA. trupp-1@medctr.osu.edu

Critical Care Nursing Clinics of North America
|January 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF.

Circulation. Heart failure·2023
Same author

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.

Circulation. Heart failure·2023
Same author

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.

Nature medicine·2021
Same author

Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure.

Circulation. Heart failure·2021
Same author

Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan.

Circulation. Heart failure·2021
Same author

Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2021
Same journal

A New Era of Nursing Innovation.

Critical care nursing clinics of North America·2026
Same journal

Advancing Outcomes Through Innovation.

Critical care nursing clinics of North America·2026
Same journal

The Arc of Nurse Anesthesia: From Battlefield Origins to Future Innovation.

Critical care nursing clinics of North America·2026
Same journal

A Sepsis-Informed Model of Accelerated Aging.

Critical care nursing clinics of North America·2026
Same journal

TeleCritical Care Reimagined: Efficiency Through Digital Communication Application.

Critical care nursing clinics of North America·2026
Same journal

Impacts and Outcomes of Intensive Care Unit Design.

Critical care nursing clinics of North America·2026
See all related articles

Heart failure incidence is rising despite advances. New drugs, devices, and trials offer hope for improved patient outcomes in managing this cardiovascular disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Technology

Background:

  • Heart failure (HF) remains a growing public health concern, with increasing incidence and prevalence.
  • Despite therapeutic advances, HF continues to be a leading cause of cardiovascular morbidity and mortality.
  • Current management strategies face challenges in effectively controlling disease progression and improving patient longevity.

Purpose of the Study:

  • To review recent pharmaceutical agents and emerging technologies for heart failure treatment.
  • To discuss ongoing clinical trials that may shape future heart failure management.
  • To highlight opportunities for enhancing patient outcomes in cardiovascular disease.

Main Methods:

  • Literature review of recently approved medications and devices for heart failure.

Related Experiment Videos

  • Analysis of key clinical trials impacting heart failure care.
  • Discussion of current and future therapeutic strategies.

    • Main Results:

    • Several new drugs and devices have been approved, offering novel treatment options.
    • Numerous clinical trials are investigating innovative approaches to heart failure management.
    • Significant potential exists for improving patient outcomes through integrated therapeutic strategies.

    Conclusions:

    • The evolving understanding of heart failure necessitates continuous adaptation of treatment paradigms.
    • Emerging pharmaceutical and technological advancements hold promise for better HF patient management.
    • A proactive approach incorporating new evidence is crucial for addressing the rising burden of heart failure.